KYONGBO PHARMACEUTICAL CO., LTD.
Price Chart
Financials
Investment Metrics(as of 2026-06-19)
| Metric | Value |
|---|---|
| Size | |
| Market Cap | 125.99B KRW |
| Revenue | 269.64B KRW |
| Net Income | -255.5M KRW |
| Total Assets | 339.07B KRW |
| Net Assets | 144.29B KRW |
| Employees | 525 |
| Value | |
| P/B | 0.87x |
| P/S | 0.47x |
| EV/EBITDA | 235.88x |
| FCF Yield | -89.87% |
| Profitability | |
| ROE | -0.18% |
| ROA | -0.08% |
| Op. Margin | 0.41% |
| Revenue Growth | 9.14% |
| Earnings Growth | -124.01% |
| Financial Health | |
| Debt Ratio | 134.99% |
| Total Debt | 140.34B KRW |
| FCF | -113.23B KRW |
| Cash | 5.20B KRW |
| Current Ratio | 0.94x |
| Dividend | |
| Div. Yield | 0.92% |
| Div. Growth | 0.00% |
| Performance | |
| 1Y Return | 7.88% |
| 1M Return | -10.53% |
| From 52W High | -43.33% |
| 1Y MDD | -40.58% |
| Trading | |
| Volume | 52,384 shares |
| Foreign Own. | 1.48% |
| Per Share | |
| EPS | 15 KRW |
| BPS | 6,036 KRW |
Company Info
Established in 1987 as a specialized Active Pharmaceutical Ingredient (API) company, the company expanded into finished pharmaceutical products in 2002 and was renamed Kyung Bo Pharm. in 2007. It markets specialized pharmaceuticals, including cardiovascular drugs and inhalant anesthetics, along with various over-the-counter drugs, while exporting cephalosporin antibiotics like Ceftriaxone domestically and internationally from its API division. Kyung Bo Pharm. is diversifying into medical devices and animal health products, such as animal pharmaceuticals and nutritional supplements. Headquartered in Asan-si, Chungcheongnam-do, the company is developing ADC (Antibody-Drug Conjugate) anticancer drug technologies for entry into the global ADC CDMO market.